TY - JOUR
T1 - Therapy for Relapsed Multiple Myeloma
T2 - Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy
AU - Dingli, David
AU - Ailawadhi, Sikander
AU - Bergsagel, P. Leif
AU - Buadi, Francis K.
AU - Dispenzieri, Angela
AU - Fonseca, Rafael
AU - Gertz, Morie A.
AU - Gonsalves, Wilson I.
AU - Hayman, Susan R.
AU - Kapoor, Prashant
AU - Kourelis, Taxiarchis
AU - Kumar, Shaji K.
AU - Kyle, Robert A.
AU - Lacy, Martha Q.
AU - Leung, Nelson
AU - Lin, Yi
AU - Lust, John A.
AU - Mikhael, Joseph R.
AU - Reeder, Craig B.
AU - Roy, Vivek
AU - Russell, Stephen J.
AU - Sher, Taimur
AU - Stewart, A. Keith
AU - Warsame, Rahma
AU - Zeldenrust, Stephen R.
AU - Rajkumar, S. Vincent
AU - Chanan Khan, Asher A.
N1 - Publisher Copyright:
© 2017 Mayo Foundation for Medical Education and Research
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Life expectancy in patients with multiple myeloma is increasing because of the availability of an increasing number of novel agents with various mechanisms of action against the disease. However, the disease remains incurable in most patients because of the emergence of resistant clones, leading to repeated relapses of the disease. In 2015, 5 novel agents were approved for therapy for relapsed multiple myeloma. This surfeit of novel agents renders management of relapsed multiple myeloma more complex because of the occurrence of multiple relapses, the risk of cumulative and emergent toxicity from previous therapies, as well as evolution of the disease during therapy. A group of physicians at Mayo Clinic with expertise in the care of patients with multiple myeloma regularly evaluates the evolving literature on the biology and therapy for multiple myeloma and issues guidelines on the optimal care of patients with this disease. In this article, the latest recommendations on the diagnostic evaluation of relapsed multiple myeloma and decision trees on how to treat patients at various stages of their relapse (off study) are provided together with the evidence to support them.
AB - Life expectancy in patients with multiple myeloma is increasing because of the availability of an increasing number of novel agents with various mechanisms of action against the disease. However, the disease remains incurable in most patients because of the emergence of resistant clones, leading to repeated relapses of the disease. In 2015, 5 novel agents were approved for therapy for relapsed multiple myeloma. This surfeit of novel agents renders management of relapsed multiple myeloma more complex because of the occurrence of multiple relapses, the risk of cumulative and emergent toxicity from previous therapies, as well as evolution of the disease during therapy. A group of physicians at Mayo Clinic with expertise in the care of patients with multiple myeloma regularly evaluates the evolving literature on the biology and therapy for multiple myeloma and issues guidelines on the optimal care of patients with this disease. In this article, the latest recommendations on the diagnostic evaluation of relapsed multiple myeloma and decision trees on how to treat patients at various stages of their relapse (off study) are provided together with the evidence to support them.
UR - http://www.scopus.com/inward/record.url?scp=85014749660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014749660&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2017.01.003
DO - 10.1016/j.mayocp.2017.01.003
M3 - Review article
C2 - 28291589
AN - SCOPUS:85014749660
SN - 0025-6196
VL - 92
SP - 578
EP - 598
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 4
ER -